Abstract
Based on previous work demonstrating the activity of cyclophosphamide and melphalan in a series of human medulloblastoma and rhabdomyosarcoma cell lines and transplantable xenografts, investigations were conducted to define the effects of combining cyclophosphamide or melphalan with VP-16. These studies demonstrated a synergistic interaction between cyclophosphamide and VP-16 and melphalan and VP-16 in the treatment of the human rhabdomyosarcoma cell line TE-671 growing in athymic mice. The combination of cyclophosphamide or melphalan with VP-16 may warrant consideration as a therapeutic strategy for solid tumors sensitive to bifunctional alkylating agents.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Alkylating Agents / administration & dosage
-
Alkylating Agents / pharmacology*
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / pharmacology*
-
DNA, Neoplasm / drug effects
-
Drug Synergism
-
Etoposide / administration & dosage
-
Etoposide / pharmacology*
-
Female
-
Male
-
Melphalan / administration & dosage
-
Melphalan / pharmacology*
-
Mice
-
Mice, Inbred BALB C
-
Neoplasm Transplantation
-
Rhabdomyosarcoma / drug therapy*
-
Transplantation, Heterologous
Substances
-
Alkylating Agents
-
DNA, Neoplasm
-
Etoposide
-
Cyclophosphamide
-
Melphalan